RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 118 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 2.52 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,522 | -85.6% | 110 | -89.7% | 0.00% | – |
| Q2 2023 | $17,529 | +2082.9% | 1,063 | +2262.2% | 0.00% | – |
| Q1 2023 | $803 | -38.7% | 45 | 0.0% | 0.00% | – |
| Q4 2022 | $1,310 | +31.0% | 45 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 45 | -65.4% | 0.00% | – |
| Q1 2022 | $1,000 | -96.9% | 130 | -95.9% | 0.00% | – |
| Q4 2021 | $32,000 | +3100.0% | 3,164 | +3195.8% | 0.00% | – |
| Q3 2021 | $1,000 | -66.7% | 96 | -29.4% | 0.00% | – |
| Q2 2021 | $3,000 | -72.7% | 136 | -72.5% | 0.00% | – |
| Q1 2021 | $11,000 | -56.0% | 494 | -40.4% | 0.00% | – |
| Q4 2020 | $25,000 | +150.0% | 829 | +79.8% | 0.00% | – |
| Q3 2020 | $10,000 | +400.0% | 461 | +339.0% | 0.00% | – |
| Q2 2020 | $2,000 | -33.3% | 105 | +6.1% | 0.00% | – |
| Q1 2019 | $3,000 | – | 99 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |